Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
| Fund/benchmark | Change | |
|---|---|---|
| Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +57.81% |
| NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +35.36% |
| Morningstar's Benchmark | Russell 2000 Biotech Growth | -- |
Announcements
- Corxel completes $287 million Series D-1 financing
- Director/PDMR Shareholding
- GSK to acquire RAPT Therapeutics
- Boston Scientific to acquire Penumbra
- Monthly Valuation Update and Factsheet
- Aktis announces $318 million IPO
- Total Voting Rights
- New investment in Yarrow Bioscience
- Monthly Valuation Update and Factsheet
- Transaction in Own Shares
More ▼
Key statistics
On Friday, RTW Biotech Opportunities Ltd (RTW:LSE) closed at 2.10, -9.48% below its 52-week high of 2.32, set on Jan 14, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Shares outstanding | 326.37m |
|---|---|
| Market cap | 695.18m USD |
| Total assets | 799.62m USD |
| Total expense ratio | -- |
| High | 2.16 |
| Low | 2.08 |
| Previous close | 2.13 |
| Average volume | 382.28k |
|---|---|
| YTD Change | -2.78% |
| Beta | 1.2442 |
| Diluted NAV (est) | 2.45 |
| Diluted NAV (last pub) | 2.45 |
| Premium/Discount | -14.29% |
| Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
